As of March 13, CDFA had confirmed two cases of equine herpesvirus myeloencephalopathy (EHM, the neurologic form of EHV-1) and 14 cases of EHV-1 with fever or mild clinical signs on premises No. 2.
Also on March 30, at Orange County premises No. 3, another horse was confirmed with EHV-1 after exhibiting neurologic clinical signs. The affected horse is reported as recovering under veterinary care.
As of March 30, CDFA has confirmed three cases of EHM and 24 cases of EHV-1 with fever or mild clinical signs on premises No. 3. Two asymptomatic positives associated with this incident were also confirmed off premises.
Herpesvirus is highly contagious among horses and can cause a variety of ailments in equids, including rhinopneumonitis (a respiratory disease usually found in young horses), abortion in broodmares, and EHM.
In many horses, the first or only sign of EHV-1 infection is fever, which can go undetected. In addition to fever, other common signs of EHV-1 infection in young horses include cough, decreased appetite, depression, and a nasal discharge. Pregnant mares typically show no signs of infection before they abort, and abortions usually occur late in gestation (around eight months) but can be earlier. Abortions can occur anywhere from two weeks to several months following infection with EHV-1.
Horses with EHM usually have a fever at the onset of the disease and might show signs of a respiratory infection. A few days later, neurologic signs such as ataxia (incoordination), weakness or paralysis of the fore- and hind limbs, urine retention and dribbling, loss of tail tone, and recumbency (inability to rise) develop.
Herpesvirus is easily spread by nose-to-nose or close contact with an infectious horse; sharing contaminated equipment including bits, buckets, and towels; or clothing, hands, or equipment of people who have recently had contact with an infectious horse. Routine biosecurity measures, including hygiene and basic cleaning and disinfection practices, should be in place at all times to help prevent disease spread.
Current EHV-1 vaccines might reduce viral shedding but are not protective against the neurologic form of the disease. Implementing routine biosecurity practices is the best way to minimize viral spread, and the best method of disease control is disease prevention.